This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignee: Mucosis B.v.. Active years: 2012-2017.
Company Filing History:
Years Active: 2012-2017
Title: The Innovative Contributions of Ronald De Groot
Introduction
Ronald De Groot is a prominent inventor based in Rotterdam, Netherlands. He has made significant contributions to the field of immunology and microbiology, particularly in the development of vaccines against microbial infections. With a total of 2 patents, his work focuses on enhancing vaccine efficacy and safety.
Latest Patents
Ronald De Groot's latest patents include a method for selecting and producing vaccine components and vaccines based thereon. This invention pertains to the field of vaccines against microbial infections, especially bacterial vaccines, with a particular emphasis on pneumococcal vaccines. The invention outlines means and methods to identify, select, and isolate a vaccine component for both passive and active immunization against microorganisms that can be targeted by opsonophagocytic cells. It describes three pneumococcal proteins: SlrA, IgA1 proteinase, and PsaA, detailing their use as vaccine components, either alone or in combination with PpmA. Additionally, the invention discusses the application of antibodies against these proteins for passive immunization and diagnostic purposes.
Career Highlights
Ronald De Groot is associated with Mucosis B.V., a company dedicated to advancing vaccine technology. His work has been instrumental in developing innovative solutions to combat bacterial infections, contributing to public health advancements.
Collaborations
Ronald collaborates with notable colleagues, including Cornelis Johannes Leenhouts and Peter Wilhelmus Maria Hermans. Their combined expertise enhances the research and development efforts at Mucosis B.V.
Conclusion
Ronald De Groot's innovative work in vaccine development showcases his commitment to improving health outcomes through scientific research. His contributions are vital in the ongoing fight against microbial infections, particularly in the realm of pneumococcal vaccines.